[HIV Glasgow 2026] HIV i-Base | Pipeline compounds for HIV treatment and prevention

Back to the "HIV and Co-Infections News" list

Report by Simon Collins, HIV i-Base

A comprehensive overview of more than 20 new HIV drugs and formulations was presented by Trip Gulick from Weill Cornell Medical College and the ACTG in a plenary lecture on new drugs and treatment strategies at HIV Glasgow 2026.

This shows a surprisingly strong pipeline with new compounds in most classes that could potentially offer a range of new long-acting combinations that are more tolerable and require fewer doses.

However, drug companies generally have a focus on developing their own in-house long-acting combinations rather than working collaboratively, other than on one of the once-weekly oral formulations.

These once-weekly options are not only closest to market but might offer the simplest positive impact on quality of life for people currently on daily oral ART.

The most exciting developments for PrEP included weekly oral lenacapavir and monthly oral alimatravir.

The report is supplemented with additional results from more than 20 additional oral and poster presentations at Glasgow 2026.

Read the full report here.


View all HIV i-Base reports from HIV Glasgow 2026


 

Source : HIV i-Base

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.